Mazdutide is a once-weekly injectable peptide and dual agonist of the GLP-1 and glucagon (GCG) receptors . Approved in China for obesity and type 2 diabetes, it suppresses appetite via GLP-1 while increasing energy expenditure and liver fat burning via GCG . Phase 3 trials show ~14% weight loss and ~80% liver fat reduction . Common side effects include mild nausea and diarrhea.